-
NEWS RELEASE
2021.01.14
Lipocine (USA, UA) announced on 12 January, 2021, positive topline Phase 2 results from LPCN1144 ongoing LiFT study in biopsy-confirmed NASH subjects.
-
NEWS RELEASE
Chemomab announces positive Phase Ib results of its SPARK study testing CM-101 in NAFLD patients
2021.01.08
Chemomab Ltd.(Israel) announced on 5 January, 2021, positive Phase Ib results of its SPARK study testing CM-101 in NAFLD patients.
-
NEWS RELEASE
Can-Fite reports on progress with its Namodenoson NASH program
2020.12.18
Can-Fite (Israel) reports on 14 December, 2020, on progress with its Namodenoson NASH program.
-
NEWS RELEASE
CytoDyn announces first patient enrolled in Phase 2 study for NASH
2020.12.02
CytoDyn (USA, KY) announced on 2 December, 2020, the first patient first visit metric was met for the Phase 2 study for NASH.
-
NEWS RELEASE
Inventiva announces FDA has granted Breakthrough Therapy designation to lanifibranor in NASH
2020.10.21
Inventiva (France) announced on 12 October, 2020, FDA haas granted Breakthrough Therapy designation to lanifibranor for the treatment of NASH.
-
NEWS RELEASE
Our clients’ presentations at AASLD ~The Liver Meeting Digital Experience~
2020.10.13
Our clients presented data on treatment of NASH using STAMTM model at the AASLD ~The Liver Meeting Digital Experience~ (November 13-16).
-
NEWS RELEASE
Virginia Comonwealth University's publication in Journal of lipid research
2020.10.07
SMC announces that Virginia Commonwealth University (Virginia) has published the results of a study using STAMTM mouse model in Journal of lipid research.
-
PUBLICATION
University of Yamanashi's publication in Clinical and Experimental Gastroenterology
2020.09.30
SMC announces that University of Yamanashi (Japan) has published the results of a study using STAMTM mouse model in Clinical and Experimental Gastroenterology.
-
NEWS RELEASE
Aldafermin improves fibrosis in patiants with NASH
2020.09.23
NGM Biopharmaceuticals, Inc. (USA) presented on August, 2020, the results of the phase 2 trial which met its primary endpoint, achieving a statistically significant reduction in liver fat content, robust fibrosis improvement, and resolution of NASH, with a favorable safety profile.
-
NEWS RELEASE
89bio announces positive topline results from its phase 1b/2a trial of BIO89-100 in NASH
2020.09.16
89bio (Israel) announced on 14 September, 2020, positive topline results from its Phase 1b/2a trial with BIO89-100 in patients with NASH. BIO89-100 treatment group demonstrated significant reductions in liver fat.
-
NEWS RELEASE
2020.09.08
Gilead Sciences, Inc. (USA) presented on August, 2020, the results of the phase 2b trial for NASH cirrhosis at EASL ~The Digital International Liver Congress™ 2020 ~.
-
UPCOMING EVENTS
Our clients’ presentations at EASL ~The Digital International Liver Congress™ 2020 ~
2020.09.01
Our clients presented data on treatment of NASH using STAMTM model at the EASL ~The Digital International Liver CongressTM 2020~ (August 27-29).